Westport, Connecticut--(Newsfile Corp. - May 22, 2024) - CYduct Diagnostics (OTC Pink: CYDX), CYductDX is a disruptive clinical-stage diagnostic company led by an experienced team of senior executives and scientists focused on proprietary technologies for the early assessment and detection of Breast Cancer., will be attending The Reg A & Crowdfunding Conference, which will take place on June 20 at the Westchester Country Club in Rye, New York.
Dom Gatto: President/CEO is open to taking meetings. Please reach out through the conference app to connect.
To register for the conference, please follow this link.
About CYduct Diagnostics
CYductDX headquartered in Westport, CT, is disrupting the breast cancer market by addressing the unmet clinical need for accurate risk assessment of breast cancer, particularly in women already at high-risk and those with dense breast tissue, so as to detect breast cancer at its earliest stages. In order to “Find It Early”, it is important to focus on the origin of virtually all breast cancers–The Mammary Ducts. The aim of CYduct is to provide specialized intraductal tools and processes that offer a suite of breast healthcare products which assess, screen, detect, monitor and treat early changes that distinguish variations in breast health. CYduct has a unique precision medicine test for women, coupled with advanced breast health medical devices for the evolutionary improvement in helping identify precancerous and cancerous lesions while still within the mammary ducts, offering the earliest detection of breast cancer.
About The Reg A & Crowdfunding Conference
The Reg A & Crowdfunding Conference is the largest annual gathering place for online investment platforms, brokers, legal and financial advisors, investors, and other dealmakers involved in Reg A and crowdfunding deals. This event is also well attended by private and public companies looking to raise capital using Reg A and Reg CF.
In 2024, the conference will broaden its focus to include Crowdfunding deals with more of the program dedicated to online deal-marketing tactics. Attendees will glean insight from experts on deal structures, fees and expenses, and the continuously changing regulatory landscape.
For further information:
Dom Gatto
President/CEO
(203) 915-7016
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.20 |
Daily Volume: | 0 |
Market Cap: | US$1.050M |
April 09, 2025 April 02, 2024 January 19, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load